Phase 2 Lymphoma Trial, Recruiting NCT06948981 Sponsor: Grit Biotechnology Condition: Lymphoma
Back to Lymphoma

Phase 2 Lymphoma Trial, Recruiting

NCT06948981
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily, have signed a consent form, and are able to follow the study's requirements.
  • People whose physical functioning is rated as 0 or 1 on a standard oncology scale (meaning they are fully active or have only minor limitations in physical activity).
  • People whose cancer cells have tested positive for a protein called CD19, confirmed through laboratory testing of blood or tissue samples.

Who may not be able to join:

  • People who have a primary immune deficiency (a condition where the immune system does not work properly from birth or early in life).
  • People who have had a serious blood clot in a deep vein or in the lungs within the past 6 months that required blood-thinning medication.
  • People who have any other medical condition that could affect how safely or accurately the trial team can assess the treatment's safety or effectiveness (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8613602100955

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Grit Biotechnology
Registry
ClinicalTrials.gov
Start date
18 April 2025
Est. completion
17 April 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of adverse events per CTCAE 5.0

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov